Maxim Group Reiterates “Buy” Rating for Actinium Pharmaceuticals Inc (ATNM)
Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)‘s stock had its “buy” rating restated by equities research analysts at Maxim Group in a report issued on Thursday. They currently have a $3.00 price objective on the biotechnology company’s stock. Maxim Group’s price objective suggests a potential upside of 331.10% from the company’s previous close.
Shares of Actinium Pharmaceuticals (NYSEMKT:ATNM) opened at 0.6959 on Thursday. The company’s 50-day moving average price is $0.61 and its 200-day moving average price is $1.08. Actinium Pharmaceuticals has a one year low of $0.54 and a one year high of $1.72. The stock’s market cap is $55.69 million.
TRADEMARK VIOLATION WARNING: “Maxim Group Reiterates “Buy” Rating for Actinium Pharmaceuticals Inc (ATNM)” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/05/maxim-group-reiterates-buy-rating-for-actinium-pharmaceuticals-inc-atnm.html.
A hedge fund recently raised its stake in Actinium Pharmaceuticals stock. Vanguard Group Inc. lifted its holdings in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) by 7.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,143,745 shares of the biotechnology company’s stock after acquiring an additional 148,579 shares during the period. Vanguard Group Inc. owned 3.67% of Actinium Pharmaceuticals worth $2,616,000 at the end of the most recent reporting period.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.